About US
Shenzhen Core Medical Technology Co., Ltd is a Chinese national high-tech enterprise founded in 2016. Core Medical is dedicated to the research and development of high-end innovative medical devices such as mechanical circulation assist systems.
Development History
Company established
2016.08
Completed construction of GMP level 10000 clean room
2019.05
Obtained A-round Financing from Lianxin capital, Puhua capital and Efung Capital
2020.08
Approval of application for innovative medical devices by the NMPA
2021.06
Corheart 6 clinical trial enrollment completed
2022.07
2019.04
Recieved the First round investment from Hetang Venture Capital
2019.12
Recognized as a national high-tech enterprise
2021.05
Obtained B-round Financing from Hillhouse capital and CICC capital
Completed type inspection of the Coreart 6.
2022.01
Approval of Corheart 6 Clinical trial
Development History
2016.08
Company established
2019.04
Recieved the First round investment from Hetang Venture Capital
2019.05
Completed construction of GMP level 10000 clean room
2019.12
Recognized as a national high-tech enterprise
2020.08
Obtained A-round Financing from Lianxin capital, Puhua capital and Efung Capital
2021.05
Obtained B-round Financing from Hillhouse capital and CICC capital
Completed type inspection of the Coreart 6.
2021.06
Approval of application for innovative medical devices by the NMPA.
2022.01
Approval of Corheart 6 Clinical trial
2022.07
Corheart 6 clinical trial enrollment completed
Core Medical focuses on the research and production of innovative medical devices in the field of heart failure, provides comprehensive solutions for heart failure treatment, and aims to become an international leader in manufacturing medical devices for heart failure diagnosis and treatment.
Good News | Corheart 6 Implantable Left Ventricular Assist System Clinical Trial Approved
2022-08-26
No Comments
On January 20, Core Medical received the “Clinical Trial Approval Opinion Sheet” approved and issued by the Medical Device Technology Review Center of the State Drug Administration, and approved the Corheart 6 implantable left ventricular assist system to conduct clinical trials.
